Skip to main content
Fig. 4 | Clinical Epigenetics

Fig. 4

From: Micro-RNA-125a mediates the effects of hypomethylating agents in chronic myelomonocytic leukemia

Fig. 4

miR-125a expression increases in CMML patients after the therapy with HMAs. a Box plot depicting the miR-125a expression levels in seven paired CMML patient specimens collected before and after treatment with HMAs. miR-125a expression was analyzed by qPCR and displayed as the log-transformed x-fold expression of the calibrator (U937 cells). Differences between expression values before and after treatment were assessed with the paired Wilcoxon signed-rank test. b,c, miR-125a expression levels in individual CMML patients with (b) or without (c) clinical response to HMA therapy. miR-125a expression levels assessed before HMA treatment were used as controls and set to 1. miR-125a levels after HMA treatment are displayed as x-fold change to the respective control sample. HMA hypomethylating agent; CP, CMML patient, Dec, decitabine; Aza, azacitidine, CR, complete response; MR, marrow response; CB, clinical benefit; PR, partial response; PD, progressive disease; NR, no response

Back to article page